{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:18:42Z","timestamp":1793146722979,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-025-00794-w","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:57:18Z","timestamp":1763467038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Controversial efficacy of antithrombin followed by recombinant thrombomodulin administration in patients with sepsis-induced disseminated intravascular coagulation: an analysis of postmarketing surveillance data"],"prefix":"10.1186","volume":"23","author":[{"given":"Yutaka","family":"Eguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagafuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"794_CR1","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jama.2014.2637","volume":"311","author":"KM Kaukonen","year":"2014","unstructured":"Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000\u20132012. JAMA. 2014;311:1308\u201316.","journal-title":"JAMA"},{"key":"794_CR2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00134-014-3496-0","volume":"40","author":"MM Levy","year":"2014","unstructured":"Levy MM, Rhodes A, Phillips GS, Townsend SR, Schorr CA, Beale R, et al. Surviving sepsis campaign: association between performance metrics and outcomes in a 7.5-year study. Intensive Care Med. 2014;40:1623\u201333.","journal-title":"Intensive Care Med"},{"key":"794_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801\u201310.","journal-title":"JAMA"},{"key":"794_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.thromres.2017.11.023","volume":"161","author":"Y Umemura","year":"2018","unstructured":"Umemura Y, Yamakawa K, Hayakawa M, Hamasaki T, Fujimi S. Screening itself for disseminated intravascular coagulation may reduce mortality in sepsis: a nationwide multicenter registry in Japan. Thromb Res. 2018;161:60\u20136.","journal-title":"Thromb Res"},{"key":"794_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/cc4822","volume":"10","author":"CJ Wiedermann","year":"2006","unstructured":"Wiedermann CJ. Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis. Crit Care. 2006;10:209.","journal-title":"Crit Care"},{"key":"794_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2552-0","volume":"23","author":"T Ito","year":"2019","unstructured":"Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care. 2019;23:280.","journal-title":"Crit Care"},{"key":"794_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri3345","volume":"13","author":"B Engelmann","year":"2013","unstructured":"Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34\u201345.","journal-title":"Nat Rev Immunol"},{"key":"794_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-017-0339-5","volume":"7","author":"X Delabranche","year":"2017","unstructured":"Delabranche X, Helms J, Meziani F. Immunohaemostasis: a new view on haemostasis during sepsis. Ann Intensive Care. 2017;7:117.","journal-title":"Ann Intensive Care"},{"key":"794_CR9","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/jth.12643","volume":"12","author":"T Tagami","year":"2014","unstructured":"Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost. 2014;12:1470\u20139.","journal-title":"J Thromb Haemost"},{"key":"794_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/jth.12786","volume":"13","author":"T Tagami","year":"2015","unstructured":"Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis- associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost. 2015;13:31\u201340.","journal-title":"J Thromb Haemost"},{"key":"794_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-017-0332-z","volume":"7","author":"T Iba","year":"2017","unstructured":"Iba T, Hagiwara A, Saitoh D, Anan H, Ueki Y, Sato K, et al. Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation. Ann Intensive Care. 2017;7:110.","journal-title":"Ann Intensive Care"},{"key":"794_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/1076029618755948","volume":"24","author":"Y Umemura","year":"2018","unstructured":"Umemura Y, Yamakawa K, Hayakawa M, Kudo D, Fujimi S. Concomitant versus individual administration of antithrombin and thrombomodulin for sepsis-induced disseminated intravascular coagulation: a nationwide Japanese registry study. Clin Appl Thromb Hemost. 2018;24:734\u201340.","journal-title":"Clin Appl Thromb Hemost"},{"key":"794_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-023-00579-z","volume":"22","author":"T Totoki","year":"2024","unstructured":"Totoki T, Makino Y, Yamakawa K, Koami H, Wada T, Ito T, et al. Effects of combination therapy of antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a systematic review and meta-analysis. Thromb J. 2024;22:10.","journal-title":"Thromb J"},{"key":"794_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/01.CCM.0000202209.42491.38","volume":"34","author":"S Gando","year":"2006","unstructured":"Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625\u201331.","journal-title":"Crit Care Med"},{"key":"794_CR15","unstructured":"MedDRA. Northrop Grumman corporation: MedDRA and MSSO. 2011. http:\/\/www.meddra.org. Accessed 28 Jan 2022."},{"key":"794_CR16","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00134-010-1991-5","volume":"36","author":"E Gayat","year":"2010","unstructured":"Gayat E, Pirracchio R, Resche-Rigon M, Mebazaa A, Mary JY, Porcher R. Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med. 2010;36:1993\u20132003.","journal-title":"Intensive Care Med"},{"key":"794_CR17","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242\u201358.","journal-title":"Stat Med"},{"key":"794_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcrc.2016.06.008","volume":"36","author":"N Yasuda","year":"2016","unstructured":"Yasuda N, Goto K, Ohchi Y, Abe T, Koga H, Kitano T. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation. J Crit Care. 2016;36:29\u201334.","journal-title":"J Crit Care"},{"key":"794_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221077096","volume":"28","author":"A Murao","year":"2022","unstructured":"Murao A, Kato T, Yamane T, Honda G, Eguchi Y. Benefit profile of thrombomodulin Alfa combined with antithrombin concentrate in patients with sepsis-induced disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2022;28:10760296221077096.","journal-title":"Clin Appl Thromb Hemost"},{"key":"794_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49855-y","volume":"13","author":"T Iba","year":"2023","unstructured":"Iba T, Maier CL, Tanigawa T, Levy JH. Risk stratification utilizing sequential organ failure assessment (SOFA) score, antithrombin activity, and demographic data in sepsis-associated disseminated intravascular coagulation (DIC). Sci Rep. 2023;13:22502.","journal-title":"Sci Rep"},{"key":"794_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13346-3","volume":"12","author":"T Wada","year":"2022","unstructured":"Wada T, Yamakawa K, Kabata D, Abe T, Ogura H, Shiraishi A, et al. Age-related differences in the survival benefit of the administration of antithrombin, recombinant human thrombomodulin, or their combination in sepsis. Sci Rep. 2022;12:9304.","journal-title":"Sci Rep"},{"key":"794_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/jth.13230","volume":"14","author":"Y Umemura","year":"2016","unstructured":"Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost. 2016;14:518\u201330.","journal-title":"J Thromb Haemost"},{"key":"794_CR23","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1160\/TH15-12-0987","volume":"115","author":"M Hayakawa","year":"2016","unstructured":"Hayakawa M, Yamakawa K, Saito S, Uchino S, Kudo D, Iizuka Y, et al. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost. 2016;115:1157\u201366.","journal-title":"Thromb Haemost"},{"key":"794_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.thromres.2016.07.016","volume":"145","author":"T Iba","year":"2016","unstructured":"Iba T, Gando S, Saitoh D, Wada H, Di Nisio M, Thachil J. Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res. 2016;145:46\u201350.","journal-title":"Thromb Res"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-025-00794-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00794-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:06:31Z","timestamp":1763510791000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-025-00794-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1186\/s12959-025-00794-w","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"1 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not applicable to this study. Our university has a sponsored research contract with the Japan Blood Products Organization (number: 381\u20135404).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}